Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.

Godtman RA, Holmberg E, Khatami A, Pihl CG, Stranne J, Hugosson J.

Eur Urol. 2016 Nov;70(5):760-766. doi: 10.1016/j.eururo.2016.03.048. Epub 2016 Apr 16.

PMID:
27090975
2.

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Määttänen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, de Koning HJ, Moss SM, Auvinen A; ERSPC Investigators..

Lancet. 2014 Dec 6;384(9959):2027-35. doi: 10.1016/S0140-6736(14)60525-0. Epub 2014 Aug 6.

3.

Guidelines on processing and reporting of prostate biopsies: the 2013 update of the pathology committee of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Van der Kwast T, Bubendorf L, Mazerolles C, Raspollini MR, Van Leenders GJ, Pihl CG, Kujala P; Pathology Committee of the European Randomized Study of Screening for Prostate Cancer (ERSPC)..

Virchows Arch. 2013 Sep;463(3):367-77. doi: 10.1007/s00428-013-1466-5. Epub 2013 Aug 6.

PMID:
23918245
4.

Prostate-cancer mortality at 11 years of follow-up.

Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Páez A, Määttänen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A; ERSPC Investigators..

N Engl J Med. 2012 Mar 15;366(11):981-90. doi: 10.1056/NEJMoa1113135. Erratum in: N Engl J Med. 2012 May 31;366(22):2137.

5.

Detection rates of cancer, high grade PIN and atypical lesions suspicious for cancer in the European Randomized Study of Screening for Prostate Cancer.

Laurila M, van der Kwast T, Bubendorf L, di Lollo S, Pihl CG, Ciatto S, Hugosson J, Määttänen L, Roobol MJ, Kujala PM.

Eur J Cancer. 2010 Nov;46(17):3068-72. doi: 10.1016/j.ejca.2010.09.035.

PMID:
21047588
6.

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.

Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl CG, Stranne J, Holmberg E, Lilja H.

Lancet Oncol. 2010 Aug;11(8):725-32. doi: 10.1016/S1470-2045(10)70146-7. Epub 2010 Jul 2.

7.

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.

Vickers AJ, Cronin AM, Aus G, Pihl CG, Becker C, Pettersson K, Scardino PT, Hugosson J, Lilja H.

Cancer. 2010 Jun 1;116(11):2612-20. doi: 10.1002/cncr.25010.

8.

Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes?

van den Bergh RC, Steyerberg EW, Khatami A, Aus G, Pihl CG, Wolters T, van Leeuwen PJ, Roobol MJ, Schröder FH, Hugosson J; Swedish and Dutch sections of the European Randomized Study of Screening for Prostate Cancer..

Cancer. 2010 Mar 1;116(5):1281-90. doi: 10.1002/cncr.24882.

9.

Variability in diagnostic opinion among pathologists for single small atypical foci in prostate biopsies.

Van der Kwast TH, Evans A, Lockwood G, Tkachuk D, Bostwick DG, Epstein JI, Humphrey PA, Montironi R, Van Leenders GJ, Pihl CG, Neetens I, Kujala PM, Laurila M, Mazerolles C, Bubendorf L, Finelli A, Watson K, Srigley J.

Am J Surg Pathol. 2010 Feb;34(2):169-77. doi: 10.1097/PAS.0b013e3181c7997b. Erratum in: Am J Surg Pathol. 2010 May;34(5):688. Pihl, C G[removed].

PMID:
20061936
10.

The European Network of Uropathology: a novel mechanism for communication between pathologists.

Egevad L, Algaba F, Berney DM, Boccon-Gibod L, Griffiths DF, Lopez-Beltran A, Mikuz G, Varma M, Montironi R; European Network of Uropathology..

Anal Quant Cytol Histol. 2009 Apr;31(2):90-5.

PMID:
19402385
11.

Screening and prostate-cancer mortality in a randomized European study.

Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Määttänen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A; ERSPC Investigators..

N Engl J Med. 2009 Mar 26;360(13):1320-8. doi: 10.1056/NEJMoa0810084. Epub 2009 Mar 18.

12.

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden.

Vickers AJ, Cronin AM, Aus G, Pihl CG, Becker C, Pettersson K, Scardino PT, Hugosson J, Lilja H.

BMC Med. 2008 Jul 8;6:19. doi: 10.1186/1741-7015-6-19.

13.

Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer.

van der Kwast TH, Ciatto S, Martikainen PM, Hoedemaeker R, Laurila M, Pihl CG, Hugosson J, Neetens I, Nelen V, Di Lollo S, Roobol MJ, Määtänen L, Santonja C, Moss S, Schröder FH.

Int J Cancer. 2006 May 15;118(10):2538-42.

14.

Is tumor vascularity in prostate core biopsies a predictor of PSA recurrence after radical prostatectomy?

Khatami A, Pihl CG, Norrby K, Hugosson J, Damber JE.

Acta Oncol. 2005;44(4):362-8.

PMID:
16120545
15.

Interobserver reproducibility of modified Gleason score in radical prostatectomy specimens.

Glaessgen A, Hamberg H, Pihl CG, Sundelin B, Nilsson B, Egevad L.

Virchows Arch. 2004 Jul;445(1):17-21. Epub 2004 May 20.

PMID:
15156317
16.
17.
18.

Consistency of prostate cancer grading results in screened populations across Europe.

Van der Kwast TH, Roobol MJ, Wildhagen MF, Martikainen PM, Määtänen L, Pihl CG, Santonja C, Bubendorf L, Neetens I, Di Lollo S, Hoedemaeker RF.

BJU Int. 2003 Dec;92 Suppl 2:88-91.

19.

Report of the Pathology Committee: false-positive and false-negative diagnoses of prostate cancer.

Van der Kwast TH, Lopes C, Martikainen PM, Pihl CG, Santonja C, Neetens I, Di Lollo S, Hoedemaeker RF.

BJU Int. 2003 Dec;92 Suppl 2:62-5. No abstract available.

20.

Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden.

Hugosson J, Aus G, Bergdahl S, Fernlund P, Frösing R, Lodding P, Pihl CG, Lilja H.

BJU Int. 2003 Dec;92 Suppl 2:39-43.

Supplemental Content

Loading ...
Support Center